Back to top

Image: Bigstock

Xeris Pharmaceuticals (XERS) is Overbought: Is A Drop Coming?

Read MoreHide Full Article

Xeris Pharmaceuticals, Inc. (XERS - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because XERS is now in overbought territory with an RSI value of 70.21.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet XERS’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions Xeris Pharmaceuticals’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of XERS’s prospects for the near term.

Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for XERS’s has also been on a downward trend over the same time period too, as the estimates have fallen 0.5% over the last two months.

If this wasn’t enough, Xeris Pharmaceuticals also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities

In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.

Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.

Click here to download this report FREE >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Xeris Pharmaceuticals, Inc. (XERS) - free report >>

Published in